Business Wire

31. BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering Of Groundbreaking Software With Customizable Interface For AI-Driven Drug Discovery 6/10/2024

    ImmunoPrecise Antibodies Ltd. (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately.

32. Every Cure Deploys BioPhy's Artificial Intelligence Platform To Accelerate Its Mission Of Repurposing Drugs For Untreated Diseases 4/30/2024

    BioPhy, an innovative AI drug development company, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

33. X-Chem Acquires Glamorous AI — Immediately Creating A Leader In DEL-Powered AI Solutions 10/28/2021

    X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery.

34. Pfizer Establishes Precision Medicine Research Collaboration With Medco 11/1/2011
    Pfizer Inc. (NYSE: PFE) announced recently that it has established a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes
35. Spectrum Pharmaceuticals To Present At The Rodman & Renshaw 10th Annual Global Healthcare Investment Conference 11/5/2008
    Spectrum Pharmaceuticals, Inc., announced today that an overview of the Company’s business strategy will be presented at the Rodman & Renshaw Annual 10th Annual Global Healthcare Investment Conference, on Tuesday, November 11, 2008, at 12:00 p.m. Eastern
36. AgilityBio And Advinus Announce Partnership To Introduce Digital Pathology Services In Pre Clinical Research 11/5/2008
    AgilityBio, a division of BioImagene Inc, and Advinus Therapeutics, a TATA enterprise, announced a partnership that will enable providing imaging services in conjunction with preclinical development services offered by Advinus
37. Progenics Selects Small-Molecule Hepatitis C Drug Candidate For Clinical Development 11/4/2008
    Progenics Pharmaceuticals, Inc.,today announced the selection of a proprietary small-molecule drug candidate, designated PRO 206, for clinical development as a treatment of hepatitis C virus (HCV) infection
38. Akorn, Inc. Announces FDA Approval Of Adenosine Injection USP, 3 mg/mL 11/3/2008
    Akorn, Inc., today announced that the U.S. Food and Drug Administration has granted approval for Akorn’s Abbreviated New Drug Application (ANDA) for Adenosine Injection USP, 3 mg/mL
39. Tripos International Completes Acquisition Of Pharsight Corporation 11/3/2008
    Tripos International, the leading provider of drug discovery informatics products and services, today announced that it has completed the acquisition of Pharsight Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development
40. Aureus Pharma To Participate In A European Consortium For Drug Cardiac Toxicity 10/30/2008
    Aureus Pharma, a leading provider of knowledge management solutions that accelerate life science discovery, announced today that they will participate in a consortium along with a number of industrial and academic research teams in a European Commission funded project entitled “preDiCT: Computational Prediction of Drug Cardiac Toxicity”